RxDoctor Payments DataLook up a doctor →

Ibrahim Ahmad, MD

Nephrology · Kettering, OHNPI 1649278110

Payments from drug & device makers

$231,688in general payments, 2019–2025

Across 570 payments — averaging $406.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$115K
  • AstraZeneca$47K
  • Bayer$31K
  • Vifor Pharma, Inc.$22K
  • Akebia Therapeutics Inc$12K
  • GSK$2K
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$12,6535%
  • Speaking & faculty fees$187,78581%
  • Travel & lodging$20,1929%
  • Food & beverage$10,2364%
  • Education$8230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$231,688 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$250,598
Medicare patients
387
Services billed
2,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl39$122,465
VelphoroSucroferric Oxyhydroxide20$84,477
KerendiaFinerenone48$44,735
FarxigaDapagliflozin Propanediol40$28,152
LokelmaSodium Zirconium Cyclosilicate17$18,949
ProsolParenteral Amino Acid 20% No.128$5,987
Sevelamer Carbonate23$4,445
ClinolipidFat Emulsion/Olive/Soy/Phospho13$4,057
Calcium Acetate24$2,006
Clonidine13$1,903
Midodrine Hcl16$1,474
Nifedipine ErNifedipine16$1,408
Torsemide41$941
Metolazone36$429
Bumetanide21$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$329$84,47720 claims
AstraZenecaFarxiga, Lokelma$47,110$47,10157 claims
BayerKerendia$30,786$44,73548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 nephrology providers in Ohio.

Other nephrology in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →